09/13/2025
👩⚕️👨⚕️🏥💉 Trials for Sickle Cell Disease: Progress, Problems & Why One Size Doesn’t Fit All
Every time I hear about a new clinical trial or breakthrough therapy for Sickle Cell Disease, my heart lights up—with hope, gratitude, and a cautious awareness. For many of us, these trials represent paths toward healing, transformation, and even cure. But there's a deeper truth we must face: not every trial works for every Sickle Cell warrior. And understanding why is as important as celebrating the victories.
1. Genetic & Biological Variability
Sickle Cell isn’t a single, uniform condition. It’s a spectrum.
There are different genotypes like HbSS, HbSC, HbSβ⁰-thalassemia, and more. Each behaves differently in the body.
Plus, modifiers like α-thalassemia or varying levels of fetal hemoglobin (HbF) can dramatically change disease manifestations.
A treatment that works by increasing HbF might help some warriors remarkably—yet do little or even backfire for others whose disease processes are influenced by different genetic factors.
2. Precision Medicine Isn’t Fully Here Yet
We talk about “tailored” or “precision” treatments, but for SCD, we’re still learning how to tailor well.
Most treatments—like penicillin and hydroxyurea—are broadly recommended across SCD genotypes.
Newer drugs like crizanlizumab (targeting P-selectin) or voxelotor (which alters hemoglobin) hint at targeted approaches. But we’re still trying to figure out who will respond best to which therapy.
3. Safety, Side Effects & Contradictory Results
Even when a trial seems promising, the risks can prompt reevaluation.
Voxelotor (Oxbryta), once celebrated, was withdrawn in 2024 due to safety concerns. Analyses indicated an imbalance in serious vaso-occlusive crises and fatal events when compared to placebo.
Crizanlizumab (Adakveo), effective for some, was recommended for withdrawal in Europe due to a lack of consistent benefit in the phase III STAND trial.
Every warrior’s body may respond differently, unpredictably—even to life-saving drugs.
4. Trial Design, Endpoints & Real-World Relevance
What counts as “success” in a trial may not always translate to real-life improvement.
Researchers have cautioned about inappropriate or poorly defined endpoints in trials. When trials don’t measure what truly matters (like quality of life, longevity, or organ protection), we risk missing the mark.
Difficulty in defining clear, universally meaningful endpoints makes it hard to compare trials—and to know for whom treatments truly help.
Small sample sizes, short trial durations, or excluding warriors with advanced organ damage can skew results and limit generalizability.
5. Enrollment & Diversity Challenges
Trials often struggle to attract enough participants, especially those who are most affected.
Many trials have terminated early due to low enrollment, sometimes because of abuse, distrust, logistical barriers, or lack of awareness.
Warriors from regions where SCD is most prevalent—like parts of Africa or India—are often left out due to lack of infrastructure, cost, or access.
Without diverse representation, we lose insights into how treatments work across cultures, environments, and genetic backgrounds.
6. Curative Options: Gene Therapies & Transplants—Not for Everyone
Yes, we have gene-editing (like Casgevy) and gene therapy (like Lyfgenia / lovotibeglogene autotemcel) now approved. We have haploidentical bone marrow transplants showing remarkable cures.
But:
These therapies are intensive, expensive, and demand specialized infrastructure.
There are serious risks: chemotherapy conditioning, immune complications, graft-versus-host disease, and more. Not every warrior is healthy enough or has access.
They are often available only to those in more developed healthcare systems—leaving out many in low-resource environments.
Why It Matters for Warriors Like Us!
We need to acknowledge that the journey toward cure, healing, or improved quality of life is not linear—or equal—for all. Recognizing why some treatments don’t work for everyone is not discouraging—it’s liberating.
It allows us to:
Speak up for diverse trial designs, better representation, and endpoints that honour our real needs.
Advocate for accessible, safe, and affordable treatments—especially in places where disease burden is highest.
Push for personalized care that sees each Sickle Cell warrior as unique, not a one-size-fits-all patient.
🥥A Deeper Layer of Healing
While clinical trials and pharmaceutical treatments are critical, I believe the medical field must also do a deeper dive into Holistic Medicinal Treatments. Systems like Ayurveda, Traditional African medicine, Chinese medicine, and other holistic sciences have been guiding healing for centuries.
🌿 Ayurveda, for example, emphasizes balance lifestyle, diet, breath, and herbs that strengthen the blood and support the body’s natural rhythms. Many warriors, myself included, have found that integrating holistic practices with medical care creates a fuller, more sustainable path of healing.
This doesn’t mean replacing one with the other—it means opening the door to a both/and approach: science and spirit, medicine and holistic wisdom, precision drugs and soul-centered practices.
Final Thought from My Heart
Clinical trials are beacons of hope—but they are still works in progress. Every warrior is different; our bodies, our struggles, our victories. Trials must reflect that. Until precision medicine becomes reality, we must stay informed, stay engaged, and stay vocal.
And in that process, never forget: your body is your first doctor. Listen to it, honour it, and trust when it calls you toward a healing path—whether that path is found in a lab, in a holistic tradition, or in the sacred space between both.
Our collective voice can shape more compassionate, more inclusive—more effective—science and care.
Thank you for following this series—now share it forward to spread awareness.
Speak On Sickle Cell - SOS
Najaam Lee's Healng Tempal
Always light and high frequency,
Najaam Lee
☆Sickle Cell Warrior☆
www.thenajmahal.com
